Novavax Inc has announced the results of an extended analysis of a late-stage trial carried out in the United Kingdom, stating that its COVID-19 vaccine provided long-term protection against the coronavirus.

NVX-CoV2373, the company’s protein-based vaccine, provide persistent protection and maintained an overall efficacy of 82.7% over a period of 6 months. A vaccine efficacy of 82.5% was maintained against both symptomatic and asymptomatic infection. Additionally, the vaccine efficacy against severe disease was 100%. The analysis was conducted from November 2020 through May 2021 before the Delta and Omicron became the dominant variants.

The company is working now on developing an Omicron-specific vaccine and expects to start the manufacturing process on a commercial level in the first quarter… (ET Healthworld – Reuters, March 1, 2022)